^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | tasadenoturev (DNX-2401) (Immunostimulant, Cell death stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma
Published date:
06/17/2014
Excerpt:
DNAtrix, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma.
